First AD

Second AD

General Approach to 3L CRC Treatment with TAS-102 + Bevacizumab

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Video Series

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting

TAS-102 combination with bevacizumab are highlighted in the 3L setting for colorectal cancer.

Selecting Optimal 3L Colorectal Cancer Treatment

Patient Case 1: 46-Year-Old Woman with Prior Hx of MSS pT4aN1b Rectosigmoid Colon Adenocarcinoma s/p Prior Treatment

Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC

Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer

Treatment Considerations With Regorafenib in Colorectal Cancer

Patient Case 3: A 57-Year-Old Man With Cecal Colon Adenocarcinoma

FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC

Monitoring and AE Management Strategies with Fruquintinib in CRC

Toxicity Considerations and Treatment Decisions in CRC

Multidisciplinary Care for Patients with CRC

Unmet Needs and Future Perspectives in Colorectal Cancer